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Regucalcin was identified as a calcium (Ca2+)-binding
protein playing an important role in maintenance of
intracellular Ca2+ homeostasis. More recently, proteomic
studies have identified it as a down-regulated gene in
mouse and human hepatocellular carcinomas. In addi-
tion, regucalcin effects in kidney and liver cells, suppres-
sing cell proliferation, inhibiting expression of oncogenes,
and increasing the expression of tumor suppressor genes,
have been described.
Prostate cancer depends on the trophic effects of
androgens, and altered Ca2+ homeostasis and signaling
have been associated with the development of this
pathology. Therefore, in the present study we analyzed
regucalcin expression, in neoplasic and non-neoplasic
prostate tissue and cells, by means of RT-PCR, western
blot and immunohistochemistry. Regucalcin localizes in
cell nuclei and cytoplasm and its expression was dimin-
ished in prostate cancer cases. Moreover, regucalcin
immunoreactivity was negatively associated with cellular
differentiation of prostate adenocarcinoma. The
effect of the non-aromatizable androgen 5-alpha-
dihydrotestosterone (DHT) on regucalcin expression in
vitro, in LNCaP prostate cancer cells, and in vivo, in a
rat animal model, was determined. Real-time PCR analy-
sis showed that DHT downregulates regucalcin expres-
sion, an effect inhibited in the presence of both
flutamide and cyclohexamide, suggesting the involve-
ment of androgen receptor and de novo protein
synthesis.
The loss of regucalcin expression in prostate cancer
cases and the regulation of its expression by androgens
suggest that it may be associated with tumor develop-
ment and/or progression.
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